PROPEL – Prospective Registry Of ParEnteraL prostanoids

 Directory of registries
PROPEL – Prospective Registry Of ParEnteraL prostanoids

Terminated registry of PAH (pulmonary arterial hypertension) patients who were treated with parenteral prostanoids.

start of the project: 01/2010

end of the project: 07/2018

Parenteral prostanoids are prescribed to patients diagnosed with pulmonary arterial hypertension (PAH) in order to maximize their exercise tolerance and to minimise their symptoms. PAH is a very rare disease with a prevalence of 1.5-2.6 patients per 100.000 population. It is therefore desirable to monitor and to assess the safety of patients treated by a specific treatment regularly and on a central level.

PAH is a disease of lung arterioles which is characterised by an increase of mean arterial pressure in the pulmonary artery (>25mm Hg at rest, >30mm Hg during exercise). It is also characterised by an increased pulmonary vascular resistance (>3 WU, Wood units).

Without adequate treatment, PAH progressively leads to heart failure and death. Median survival rate in untreated patients is around 2.8 years. Symptoms are non-specific, especially in early stages of the disease. Severity of symptoms considerably correlates with the prognosis of a given patient. The most common symptoms involve exertional dyspnoea, fatigue, chest pain and syncope.

PROPEL – the Prospective Registry Of ParEnteraL prostanoids – was focused on the collection of clinical data on PAH patients as well as data on therapeutic effects and safety of parenteral prostanoids.

Primary objective of the project:

  • collection of clinical data on PH patients treated with parenteral prostanoids

Secondary objectives of the project:

  • assessment of effectiveness of the chosen therapy,
  • assessment of safety of the chosen therapy,
  • analysis of survival in relation to monitored clinical factors,
  • assessment of quality of life in PAH patients treated with parenteral prostanoids.

Other important information:

  • Expert guarantors: Pavel Jansa, MD (General University Hospital in Prague, Czech Republic), Prof. Dr. Irene Lang (Medical University of Vienna, Austria), Prof. Jean-Luc Vachiery, MD (Erasme Hospital, Brussels, Belgium)
  • Funding: United Therapeutics Europe, Ltd.
  • Partners: specialized centres in six European countries (you can find more detailed information on the website of the PROPEL project)
  • Brief overview of results: you can find more detailed information on the website of the PROPEL project
PROPEL: registry of PAH (pulmonary arterial hypertension) patients who have been treated with parenteral prostanoids